Expected outcomes and patients’ selection before chemoembolization—“Six-and-Twelve or Pre-TACE-Predict” scores may help clinicians: Real-life French cohorts results

Table 2 Baseline characteristics of hepatocellular carcinoma patients undergoing transarterial chemoembolization treatment

Demographic variables	Marseille/Nancy cohort, n = 324	Nice cohort, n = 137
Age, median (Q1-Q3), yr	68 (62-74)	67 (57-75)
Gender n (%)
Male/Female	276 (85)/48 (15)	126 (92%)/11 (8)
Liver disease n (%)
HCV/HBV/Alcoholism/MS/other	129 (40)/14 (4)/122 (38)/42 (13)/17 (5)	55 (40)/8 (6)/44 (32)/11 (8)/19 (14)
ECOG (PS-0/1) n (%)	324 (100)	69 (50)/68 (50)
Cirrhosis n (%)	311 (96)	118 (86)
Tumor variables
Tumor size, mm, median (Q1-Q3)	35 (25-50)	46 (25-70)
Nodule (s): n (%) 1/2/3/4/≥ 5	95 (29)/72 (22)/80 (25)/38 (12)/39 (12)	20 (15)/22 (16)/63 (46)/32 (23)/0
Vascular invasion	0	24 (18%)
Laboratory variables
AFP, ng/mL, median (Q1-Q3)	16.3 (6.0-120.3)	18 (1-600)
PT (%), median (Q1-Q3)	76 (64-88)	90 (79-100)
Albumin (g/L), median (Q1-Q3)	35 (28-38)	37 (33-41)
Total bilirubin (mcmol/L), median (Q1-Q3)	19.0 (13.7-28.7)	11 (8-19)
Platelet count, 109/L, Median (IQR)	106 (82-153)	-
Child-Pugh grade n (%) A/B7	249 (77)/75 (23)	126 (92)/11 (8)
ALBI grade 1/ 2/3 n (%)	64 (20)/230 (71)/30 (9)	52 (38)/79 (58/6 (4)
BCLC stage A/B/C n (%)	145 (45)/179 (55)/0	0/58 (42)/79 (58)
“6 and 12” score allocation n (%)
≤ 6/6-12/> 12	154 (48)/163 (50)/7 (2)	51 (37)/73 (53)/13 (10)
NIACE score allocation n (%)
≤ 1/1.5-3/> 3	168 (52/134 (41)/22 (7)	41 (30)/72 (52)/24 (18)
1Pre-TACE allocation n (%)
C-1/C-2/C-3/C-4	47 (15)/144 (44/109 (34)/23 (7)	32 (23)/35 (26)/47 (34)/23 (17)
TACE session, mean (SD)	2.7 ± 1.8	4.0 ± 2.3
Radiological response (after first TACE)
CR/PR/SD2/PD n (%)	176 (54)/67 (21)/15 (5)/66 (20)	34 (25)/88 (64)/6 (4)/9 (7)

¹Available data for 323 patients for score calculation. HCC: Hepatocellular carcinoma; TACE: Transarterial chemoembolization; HCV: Hepatitis C virus; HBV: Hepatitis B virus; MS: Metabolic syndrome; ECOG (PS): Eastern Cooperative Oncology Group (performance status); AFP: Alpha-fetoprotein; PT: Prothrombin Time; ALBI: Albumin-Bilirubin; BCLC: Barcelona Clinic Liver Cancer; “6 and 12”: “Six-and-Twelve”; NIACE: Number of tumor(s), Infiltrative hepatocellular carcinoma, Alpha-fetoprotein, Child-Pugh class, Eastern Cooperative Oncology Group Performance Status; C: Category; SD: Standard deviation; CR: Complete response; PR: Partial response; SD²: Stable disease; PD: Progressive disease.